Jennifer Buell - Agenus Pres Therapeutics
| AGEN Stock | USD 3.74 0.16 4.10% |
Executive
Dr. Jennifer S. Buell is Chief Operating Officer of the Company. Since joining Agenus in 2013, Dr. Buell has served as the Head of Global RD operations, Head of Research, and most recently as Chief Communications and External Affairs Officer. During her tenure, Jen helped advance the expansion of Agenus from a neoantigen vaccine company to a global, fullyintegrated platform company with a unique pipeline of immune modulating antibodies, cancer vaccines, adjuvants, and adoptive cell therapies. Today, Agenus has major collaborations with Merck and Incyte, a demonstrated track record of delivering on operational commitments, and has outpaced pharma in delivering new discoveries to the clinic. In her new role, Dr. Buell will assume responsibility for Research, Clinical Development, Manufacturing, Commercial Operations, and relevant supportive functions. since 2018.
| Age | 49 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Phone | 781 674 4400 |
| Web | https://www.agenusbio.com |
Jennifer Buell Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jennifer Buell against Agenus stock is an integral part of due diligence when investing in Agenus. Jennifer Buell insider activity provides valuable insight into whether Agenus is net buyers or sellers over its current business cycle. Note, Agenus insiders must abide by specific rules, including filing SEC forms every time they buy or sell Agenus'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jennifer Buell over a year ago Acquisition by Jennifer Buell of 500000 shares of Mink Therapeutics subject to Rule 16b-3 | ||
Jennifer Buell over a year ago Acquisition or disposition of Mink Therapeutics securities by Jennifer Buell | ||
Jennifer Buell over a year ago Payment of 25000 shares by Jennifer Buell of Mink Therapeutics subject to Rule 16b-3 | ||
Jennifer Buell over a year ago Exercise or conversion by Jennifer Buell of 695750 shares of Mink Therapeutics subject to Rule 16b-3 |
Agenus Management Efficiency
The company has return on total asset (ROA) of (0.2195) % which means that it has lost $0.2195 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.7883) %, meaning that it created substantial loss on money invested by shareholders. Agenus' management efficiency ratios could be used to measure how well Agenus manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Kirk MD | PDS Biotechnology Corp | 73 | |
| Michael Loiacono | Marker Therapeutics | 58 | |
| Ronald Filippo | Madrigal Pharmaceuticals | N/A | |
| Bo Kara | Mereo BioPharma Group | N/A | |
| Spencer JD | PDS Biotechnology Corp | 55 | |
| Patricia Allison | Marker Therapeutics | N/A | |
| Michael Wolf | Affimed NV | 58 | |
| Robert MD | Edgewise Therapeutics | N/A | |
| Nadia Agopyan | Marker Therapeutics | N/A | |
| Dana Lynch | Adaptimmune Therapeutics Plc | N/A | |
| Michael Morneau | Viking Therapeutics | 60 | |
| Gerald Garrett | Marker Therapeutics | N/A | |
| Gregory Conn | PDS Biotechnology Corp | 70 | |
| Edward Chiang | Madrigal Pharmaceuticals | N/A | |
| Mary Sandin | Affimed NV | N/A | |
| David Ege | ADC Therapeutics SA | 51 | |
| Cintia PharmD | Adaptimmune Therapeutics Plc | 50 | |
| Sanjay Zaveri | PDS Biotechnology Corp | N/A | |
| Kristen HarringtonSmith | ADC Therapeutics SA | 51 | |
| MBA MD | X4 Pharmaceuticals | 62 | |
| Robert Arbeit | X4 Pharmaceuticals | 77 | |
Management Performance
| Return On Equity | -12.79 | ||||
| Return On Asset | -0.22 |
Agenus Inc Leadership Team
Elected by the shareholders, the Agenus' board of directors comprises two types of representatives: Agenus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Agenus. The board's role is to monitor Agenus' management team and ensure that shareholders' interests are well served. Agenus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Agenus' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Julie DeSander, Chief Officer | ||
| Alfred Dadson, Chief Officer | ||
| Eric Humes, Chief Officer | ||
| Regina Grebla, VP Communications | ||
| Dr MBA, Chief Officer | ||
| John Castle, Head Bioinformatics | ||
| Zack Armen, Head Development | ||
| Dhan Chand, Scientific Discovery | ||
| Christine Klaskin, Principal Accounting Officer and VP of Fin. | ||
| Jennifer Buell, Pres Therapeutics | ||
| Nils MD, Chief Officer | ||
| Tracy Clemente, Chief Officer | ||
| Garo Armen, Founder, Executive Chairman, CEO and Chairman of Bus. and Devel. Advisory Committee | ||
| Todd MD, Member Advisor | ||
| Craig Winter, Chief Officer | ||
| Robin JD, Chief Officer | ||
| Stephanie Fagan, Chief Officer |
Agenus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Agenus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -12.79 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (1.42) % | ||||
| Operating Margin | (1.33) % | ||||
| Current Valuation | 116.25 M | ||||
| Shares Outstanding | 23.61 M | ||||
| Shares Owned By Insiders | 1.35 % | ||||
| Shares Owned By Institutions | 37.12 % | ||||
| Number Of Shares Shorted | 2.94 M | ||||
| Price To Earning | 10.52 X |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agenus Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agenus. If investors know Agenus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agenus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Agenus Inc is measured differently than its book value, which is the value of Agenus that is recorded on the company's balance sheet. Investors also form their own opinion of Agenus' value that differs from its market value or its book value, called intrinsic value, which is Agenus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agenus' market value can be influenced by many factors that don't directly affect Agenus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agenus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Agenus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agenus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.